Biodesix to Participate in Three Investor Conferences in November
29 Ottobre 2024 - 11:00AM
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions
company with a focus in lung disease, today announced Scott Hutton,
Chief Executive Officer, and Robin Cowie, Chief Financial Officer,
will participate in three upcoming investor conferences:
Craig-Hallum 15th
Annual Alpha Select Conference1x1 MeetingsDate:
Tuesday, November 19, 2024Location: New York, NY
Wolfe Research Healthcare Conference 20241x1
MeetingsDate: Wednesday, November 20, 2024Location: New York,
NY
Canaccord Genuity Medtech, Diagnostics and Digital
Health & Services Forum Presentation and 1x1
MeetingsPresentation Date and Time: Thursday, November 21, 2024 at
1:00 PM ETLocation: New York, NY
The presentation will be webcast live and available for replay
under “News & Events” in the Investors section of the Company's
website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company with five
Medicare-covered tests available for patients with lung diseases.
The blood-based Nodify Lung® Nodule Risk Assessment, consisting of
the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of
malignancy in pulmonary nodules, enabling physicians to better
triage patients to the most appropriate course of action. The
blood-based IQLung™ test portfolio for lung cancer patients
integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS®
test, and the VeriStrat® test to support treatment decisions across
all stages of lung cancer and expedite personalized treatment. In
addition, Biodesix collaborates with the world’s leading
biopharmaceutical companies to provide biomarker discovery,
diagnostic test development, and clinical trial support services.
For more information, visit biodesix.com.
Note: Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS,
VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered
trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad
Laboratories, Inc.
Contacts:
Media:Natalie St.
DenisNatalie.StDenis@biodesix.com1-720-925-9285
Investors:Chris
Brinzeychris.brinzey@westwicke.com1-339-970-2843
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Dic 2023 a Dic 2024